Abstract
This work is aimed at evaluating the effect of repeated intracavernosal injection (ICI) self-injection on the peak systolic velocity (PSV) and the diameter of cavernosal arteries. Sixty erectile dysfunction (ED) patients who were positive responders for ICI therapy were studied. Pharmacopenile duplex ultrasonography (PPDU) was carried out before starting ICI and after 10 doses of home therapy in an open-label uncontrolled study. There was significant increase in the cavernosal artery diameter and their PSV before and after injection. Cavernosal arteries diameter before injection in both right and left sides was 0.64±0.13 and 0.63±0.12 mm at the start and became 0.81±0.22 and 0.79±0.22 mm respectively at the end with significant differences (P<0.001). Cavernosal arteries diameter after injection in both right and left sides was 1.10±0.18 and 1.09±0.19 mm at the start and became 1.34±0.39 and 1.27±0.33 mm respectively at the end with significant differences (P<0.001). PSV at the start was 33.77±13.26 and 32.33±8.09 cm/s on both right and left sides and became 44.4±1.19 and 46.1±5.86 cm/s respectively at the end with significant differences (P<0.001). It is concluded that repeated ICI improves arterial erectile response with associated increase in PSV and cavernosal artery diameters.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
McKinlay JB . The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000; 12: S6–S11.
Hellstrom WJ . The molecular basis of erectile physiology: from bench to bedside. J Androl 2002; 23: S3–S4.
Burnett AL . Nitric oxide regulation of penile erection: biology and therapeutic implications. J Androl 2002; 23: S20–S26.
Virag R . Intracavernous injection of papaverine for erectile failure 1982. J Urol 2002; 167: 1196.
Derouet H, Osterhage J, Sittinger H . Erectile dysfunction: Epidemiology, Physiology, Etiology, Diagnosis and Therapy. Urologe A 2004; 43: 197–207.
Porst H . The rationale for PGE1 in erectile failure; a survey of worldwide experience. J Urol 1996; 155: 802–815.
van der Windt F, Dohle GR, van der Tak J, Slob AK . Intracavernosal injection therapy with and without sexological counseling in men with erectile dysfunction. BJU Int 2002; 89: 901–904.
Benson CB, Aruny JE, Vickers MA . Correlation of duplex sonography with arteriography in patients with erectile dysfunction. AJR Am Roentgenol 1993; 160: 71–73.
Broderick GA . Non invasive vascular imaging for erectile dysfunction. In: Carson C, Kirby RS, Goldstein I (eds). Textbook of Erectile Dysfunction. Isis Media: Oxford, 1999 pp 233–256.
Montorsi F, Salonia A, Pompa P, Cestari A, Guazzoni G, Barbieri L et al. Current status of local penile therapy. Int J Impot Res 2002; 14: 70–81.
Gerstenberg TC, Nordling J, Hald T, Wagner G . Standardized evaluation of erectile dysfunction in 95 consecutive patients. J Urol 1989; 141: 857–862.
Kerfoot WW, Carson CC . Pharmacologically induced erections among geriatric men. J Urol 1991; 146: 1022–1024.
Montorsi F, Guazzoni G, Bergamaschi F, Ferini-Strambi L, Barbieri L, Rigatti P . Four-drug intrcavernous penile therapy for corporeal veno-occlusive dysfunction. J Urol 1993; 149: 1291–1295.
Wespes E . Erectile dysfunction, physiologic approach, diagnosis and therapy. Bull Mem Acad R Med Belg 2006; 161: 151–158.
Ravnik-Oblak M, Oblak C, Vodusek DB . Intracavernous injection of PGE1 in impotent diabetic men. Int J Impot Res 1990; 11: 143.
Bennett AH, Carpenter AJ, Barada JH . Improved vasoactive drug combination for pharmacological erection program. J Urol 1991; 146: 1564–1565.
Gerber GS, Levine LA . Pharmacological erection program using prostaglandin E1. J Urol 1991; 146: 786–789.
Sharlip I . Does natural erectile function improve following intracavernous injections of vasoactive drugs? Int J Impot Res 1997; 9: 193–196.
Virag R, Shoukry K, Floresco J, Nollet F, Greco E . Intracavernous self injection of vaso active drugs in treatment of impotence; 8 year experience with 615 cases. J Urol 1991; 145: 287–293.
Marshall GA, Breza J, Lue TF . Improved hemodynamic response after long-term intracavernous injection for impotence. Urology 1994; 43: 844–848.
Moreira Jr SG, Brannigan RE, Spitz A, Orejuela FJ, Lipshultz LI, Kim ED . Side effects profile of sildenafil citrate (Viagra) in clinical practice. Urology 2000; 56: 474–476.
McMahon CG . High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction. Int J Impot Res 2002; 14: 533–538.
Hatzichristou DG, Apostolidis A, Tzortzis V, Ioannides E, Yannakoyorgos K, Kalinderis A . Sildenafil versus intracavernous injection therapy: efficacy and preference in patients on intracavernous injection for more than 1 year. J Urol 2000; 164: 1197–1200.
Richter S, Vardi Y, Ringel A, Shalev M, Nissenkorn I . Intracavernous injections: still the gold standard for treatment of erectile dysfunction in elderly men. Int J Impot Res 2001; 13: 172–175.
Nagai A, Kusumi N, Tsuboi H, Ishii K, Saika T, Nasu Y et al. Intracavernous injection of prostaglandin E1 is effective in patients with erectile dysfunction not responding to phosphodiesterase 5 inhibitors. Acta Med Okayama 2005; 59: 279–280.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Awad, H., El-Karaksy, A., Mostafa, T. et al. Repeated intracorporeal self-injection: effect on peak systolic velocity and cavernosal artery diameter. Int J Impot Res 19, 505–508 (2007). https://doi.org/10.1038/sj.ijir.3901563
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.ijir.3901563


